Cite
Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
MLA
Burgess, Stephen, et al. “Association OfLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies.” JAMA Cardiology, vol. 3, July 2018, p. 619. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2d0351ef9f388bfc345e4bfe424eb98a&authtype=sso&custid=ns315887.
APA
Burgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., Bolton, T. R., Peters, J. E., Kamstrup, P., Tybjærg-Hansen, A., Benn, M., Langsted, A., Schnohr, P., Vedel-Krogh, S., Kobylecki, C. J., … Riboli, E. (2018). Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 3, 619.
Chicago
Burgess, Stephen, Brian A. Ference, James R. Staley, Daniel F. Freitag, Amy M. Mason, Sune F. Nielsen, Peter Willeit, et al. 2018. “Association OfLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies.” JAMA Cardiology 3 (July): 619. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2d0351ef9f388bfc345e4bfe424eb98a&authtype=sso&custid=ns315887.